![Tony Fiorino](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Tony Fiorino
Direttore/Membro del Consiglio presso
IMMUNE PHARMACEUTICALS, INC.
Profilo
Anthony S.
Fiorino is the founder of EnzymeRx LLC, which was founded in 2008.
He held the title of President & Chief Executive Officer in 2012.
He is currently working as a Director at Immune Pharmaceuticals, Inc. since 2017.
In his former positions, he served as the Chief Executive Officer at Brainstorm Cell Therapeutics, Inc. from 2014 to 2015, President & Chief Executive Officer at Triumvira Immunologics, Inc. from 2015 to 2017, and as an Independent Director at Navidea Biopharmaceuticals, Inc. from 2016 to 2017.
He also worked as a Managing Director at Greywall Asset Management LP from 2013 to 2014.
Additionally, he held positions at Pequot Capital Management, Inc., Sands Point Partners LP, JPMorgan Services (Malaysia) Sdn.
Bhd., electroCore, Inc., and Alchimia Partners LLC.
Dr. Fiorino completed his undergraduate degree at Massachusetts Institute of Technology in 1989 and received his doctorate degree from Albert Einstein College of Medicine, Inc. in 1996 and 1995.
Posizioni attive di Tony Fiorino
| Società | Posizione | Inizio |
|---|---|---|
| IMMUNE PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 06/03/2019 |
Precedenti posizioni note di Tony Fiorino
| Società | Posizione | Fine |
|---|---|---|
| NAVIDEA BIOPHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 09/10/2017 |
Triumvira Immunologics, Inc.
 Triumvira Immunologics, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceutical products | Amministratore Delegato | 01/01/2017 |
| BRAINSTORM CELL THERAPEUTICS INC. | Amministratore Delegato | 01/11/2015 |
Greywall Asset Management LP
 Greywall Asset Management LP Investment ManagersFinance Profile Unavailable | Corporate Officer/Principal | 01/05/2014 |
EnzymeRx LLC
 EnzymeRx LLC BiotechnologyHealth Technology Operates as biotechnology company developing uricase-PEG 20 for the treatment of resistant and refractory gout and related indications | Amministratore Delegato | 01/12/2012 |
Formazione di Tony Fiorino
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
93
Relazioni di 1° grado
13
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 13 |
|---|---|
Navidea Biopharmaceuticals, Inc.
 Navidea Biopharmaceuticals, Inc. Medical SpecialtiesHealth Technology Develops and commercializes precision diagnostics and radiopharmaceutical agents | Health Technology |
Pequot Capital Management, Inc.
 Pequot Capital Management, Inc. Investment ManagersFinance Pequot Capital Management's investment philosophy is based on deep fundamental research and unbiased thematic analysis to identify and capitalize on market inefficiencies across an industry sector or a company's lifecycle. The firm invests in public equities, private equity, venture capital, distressed securities and a variety of fixed-income securities. Pequot Capital Management tends to invest in the stocks of US small-cap companies in the consumer services, health technology and commercial services sectors. They maintain a very high turnover rate. | Finance |
Brainstorm Cell Therapeutics, Inc.
 Brainstorm Cell Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company, which develops innovative adult stem cell therapeutic products | Health Technology |
Sands Point Partners LP | |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
JPMorgan Services (Malaysia) Sdn. Bhd.
 JPMorgan Services (Malaysia) Sdn. Bhd. Financial ConglomeratesFinance Operates an investment company | Finance |
EnzymeRx LLC
EnzymeRx LLC BiotechnologyHealth Technology Operates as biotechnology company developing uricase-PEG 20 for the treatment of resistant and refractory gout and related indications | Health Technology |
Albert Einstein College of Medicine, Inc.
 Albert Einstein College of Medicine, Inc. Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
electroCore, Inc.
 electroCore, Inc. Medical SpecialtiesHealth Technology Develops non-invasive neuromodulation therapies | Health Technology |
Immune Pharmaceuticals, Inc.
 Immune Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for the treatment of cancer and pain | Health Technology |
Greywall Asset Management LP
Greywall Asset Management LP Investment ManagersFinance Profile Unavailable | Finance |
Triumvira Immunologics, Inc.
Triumvira Immunologics, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceutical products | Health Technology |
Alchimia Partners LLC
 Alchimia Partners LLC Miscellaneous Commercial ServicesCommercial Services Provides business support services | Commercial Services |
